1,899 results on '"Wu, Y-L"'
Search Results
2. On structure of topological entropy for tree-shift of finite type
3. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
4. Ultrafast Quasiparticle Dynamics and Electron-Phonon Coupling in (Li0.84Fe0.16)OHFe0.98Se
5. Prevalence and trend of gonorrhea in female sex workers and men having sex with men in China: a systematic review and meta-analysis
6. Strong Pseudospin-Lattice Coupling in Sr3Ir2O7: Coherent Phonon Anomaly and Negative Thermal Expansion
7. Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC
8. Toward the prevention of coronavirus infection: what role can polymers play?
9. Ultrafast Dynamics Evidence of High Temperature Superconductivity in Single Unit Cell FeSe on SrTiO3
10. Osimertinib versus platinum–pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis
11. Reproductive outcomes in infertile couples undergoing intracytoplasmic sperm injection with a male partner exhibiting chromosomal translocation or inversion
12. Diffraction-limited Visible Light Images of Orion Trapezium Cluster With the Magellan Adaptive Secondary AO System (MagAO)
13. High Resolution H alpha Images of the Binary Low-mass Proplyd LV 1 with the Magellan AO System
14. Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS
15. Anomalous Silicate Dust Emission in the Type 1 LINER Nucleus of M81
16. EFFICIENT UAV FLIGHT PLANNING FOR LOD2 CITY MODEL IMPROVEMENT
17. 44P Exploratory analysis of peripheral pharmacodynamic (PD) biomarkers after sitravatinib (Sitra) and tislelizumab (TIS) in advanced solid tumors: SAFFRON-103
18. WS02.13 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)
19. P2.12-08 Response to Emerging Targeted Therapies and Genomic Analysis for NSCLC with Leptomeningeal Metastases and Uncommon Mutations
20. P2.03-05 Clinical Impact of Genomic Characterization in Induced Oligometastatic Non-small Cell Lung Cancer
21. P1.27-05 Two- and Three-dimensional Radiomic Measurements for Clinical Stage IA Lung Adenocarcinoma: Less is More
22. P2.04-03 EGRET: First-in-human Study of the Novel Antibody-drug Conjugate AZD9592 ± Anti-cancer Agents in Advanced Solid Tumours
23. EP08.01-02 Single-Cell RNA Sequencing Reveals Unique Immune Landscape in Rare-Mutant Non-Small Cell Lung Cancer Undergoing Chemo-Immunotherapy
24. P2.05-16 Immune Suppressive Microenvironment in Liver Metastases Contributes to Organ-Specific Response of Immunotherapy
25. P1.26-03 Retrospective Comparison of Robotic- and Video-assisted Thoracic Surgery after Neoadjuvant Therapy for Non-small Cell Lung Cancer
26. P1.22-03 Ventana ALK (D5F3) Immunohistochemistry Improves the Accuracy of Pathologic Assessment after Neoadjuvant ALK-TKIs for ALK-Positive NSCLC
27. EP09.04-02 Preoperative Circulating Tumor DNA Status Predicts Pathological Response in Advanced Non-small Cell Lung Cancer
28. P1.27-03 Neoadjuvant PD-1 Blockade Plus Platinum-based Chemotherapy for EGFR-mutant NSCLC (CTONG2104): An Interim Analysis
29. P2.06-07 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901)
30. EP08.01-01 Subtyping EGFR-mutated NSCLC Patients with Adjuvant TKIs or Chemotherapy Using Deep Radiomic Signatures
31. OA21.05 Tepotinib + Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
32. P1.23-09 Cerebrospinal Fluid ctDNA Based Therapy Associated with Survival of CNS Metastases in Advanced NSCLC: A Large Scale, Comprehensive Study
33. MA13.08 Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations
34. P1.03-01 Dynamic Transcriptomic Characterization Changes of Early Stage Lung Adenocarcinoma as per the Incrassation of Consolidation Tumor Ratio
35. P1.09-02 Midkine Dependent Immunosuppressive Environment in Cerebrospinal Fluid May Promote Leptomeningeal Metastases of EGFR mutant NSCLC
36. Physics at BES-III
37. Exclusive $B \to PV $ Decays and CP Violation in the General two-Higgs-doublet Model
38. 1279P First-line lorlatinib vs crizotinib in Asian patients with ALK+ non-small cell lung cancer (NSCLC): 5-year outcomes from the CROWN study
39. 1/m_Q Corrections to B -> rho l nu Decay and |V_{ub}
40. Correlation of extent of ALK FISH positivity and crizotinib efficacy in three prospective studies of ALK-positive patients with non-small-cell lung cancer
41. The prevalence and influencing factors for child neglect in a rural area of Anhui province: a 2-year follow-up study
42. B Physics and Hadronic Matrix Elements
43. Lifetime Difference and Endpoint effect in the Inclusive Bottom Hadron Decays
44. A More Precise Extraction of |V_{cb}| in HQEFT of QCD
45. 1/m_Q order contributions to B \to \pi l \nu decay in HQEFT
46. The Effects of Relativistic Corrections on Cosmological Parameter Estimations from SZE Cluster Surveys
47. HQEFT as A Large Component QCD and Comments on The Incompleteness of HQET
48. Exclusive B-meson Rare Decays and General Relations of Form Factors in Effective Field Theory of Heavy Quarks
49. Heavy to Light Meson Exclusive Semileptonic Decays in Effective Field Theory of Heavy Quark
50. V_{ub}, V_{cb} and Decay Constants in Effective Field Theory of Heavy Quarks
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.